Beneath the conditions of the agreement, Allergan will make an upfront payment of $50 million to Mimetogen and can fund phase 3 advancement of tavilermide. Mimetogen can additionally be eligible for receive potential milestone royalties and payments based on commercialization of the product. Tavilermide is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the optical attention responsible for the maintenance of corneal nerves and epithelium. Tavilermide is normally differentiated from other investigational therapies in dry eye disease since it induces the creation of mucin, a normally occurring element of the tear film, and works prior to inflammation upstream. Allergan is committed to leading in the advancement of novel therapies in attention care and dry eye disease, said David Nicholson, Executive Vice President and President, Global Brands Research and Advancement at Allergan.Non-GAAP offering, general and administrative expenses for Q1 2011 had been $57.8 million, in comparison to $44.9 million for Q1 2010. The upsurge in non-GAAP SG&A expenses primarily reflected costs associated with the expansion of the Company’s commercial operations in fresh geographies. First Quarter GAAP Financial Outcomes: Alexion reported GAAP net gain of $26.8 million, or $0.28 per talk about, for Q1 2011, including a negative after-tax impact of $6.9 million, or $0.07 per share, from costs linked to the Taligen Therapeutics and Orphatec Pharmaceuticals acquisitions during the quarter, in comparison to Q1 2010 GAAP net gain of $20.9 million, or $0.23 per talk about.